New Enzyme Could Make GLP-1 Drugs Last Longer

If you take a GLP-1 medication like Ozempic or Wegovy, you already know the drill: one injection per week, same day, every week. But new research suggests that routine could eventually change, and the reason comes down to a single enzyme your body has been quietly using to break down these drugs all along.

What Scientists Actually Found

Researchers have identified a previously unknown enzyme that degrades GLP-1 hormones in the body. GLP-1, short for glucagon-like peptide-1, is the hormone that these medications mimic or amplify to help regulate blood sugar and reduce appetite.

Until now, scientists knew that an enzyme called DPP-4 (dipeptidyl peptidase-4) was one of the main culprits responsible for breaking down natural GLP-1 hormones quickly. Drug developers already account for this by chemically modifying semaglutide (the active ingredient in Ozempic and Wegovy) to resist DPP-4 degradation. But this newly identified enzyme appears to be an additional breakdown pathway that was not previously factored into drug design.

In laboratory tests, blocking this newly discovered enzyme extended the half-life of semaglutide by up to 40%. Half-life is the time it takes for the concentration of a drug in your body to drop by half. A longer half-life generally means the drug stays active longer, potentially allowing for less frequent dosing.

Why Half-Life Matters for GLP-1 Patients

You might wonder why this is a big deal when weekly dosing is already manageable for most people. Here's the practical picture.

Current Dosing Windows Have Real Limitations

Even with weekly injections, semaglutide blood levels fluctuate throughout the week. Some patients notice that appetite control feels slightly weaker toward the end of the week before their next dose. A longer-acting formulation could smooth out those peaks and valleys, delivering more consistent appetite suppression and blood sugar management.

Missing Doses Has Consequences

Real-world adherence to weekly injections is not perfect. Travel, supply shortages, cost gaps, or simply forgetting can disrupt dosing schedules. A drug that stays active longer in the body could reduce the impact of an occasional missed or delayed dose, making treatment more forgiving in practice.

Monthly Dosing Could Become Realistic

If this enzyme-blocking approach eventually makes it into approved medications, monthly injections could become feasible. That would be a significant shift in convenience and potentially in cost, since less drug may be needed per dose to achieve the same effect.

How the Science Works

To understand why this discovery matters, it helps to know how GLP-1 drugs are designed right now.

Natural GLP-1 hormones released by your gut after eating are broken down within minutes. Drug developers engineered semaglutide to survive much longer by attaching it to a fatty acid chain that binds to albumin, a protein in your blood. That binding protects it from rapid clearance and allows for once-weekly dosing.

The newly identified enzyme appears to work through a separate mechanism, one that even the albumin-binding protection does not fully block. Think of it like a lock with two keys. Existing drug design only accounted for one of those keys. This research identified the second one.

By developing a compound that inhibits this second enzyme, or by redesigning the drug molecule itself to resist it, pharmaceutical researchers could potentially push weekly injections toward bi-weekly or even monthly dosing without sacrificing effectiveness.

What This Means for Tirzepatide Too

This research focused specifically on semaglutide, but the implications likely extend further. Mounjaro and its weight loss version Zepbound contain tirzepatide, a dual GIP/GLP-1 receptor agonist that also includes a GLP-1 component. If this enzyme degrades GLP-1 activity broadly, tirzepatide could face similar limitations.

Researchers will need to investigate whether this enzyme acts on tirzepatide's GLP-1 component, and whether blocking it would extend tirzepatide's effective duration as well. The early focus on semaglutide makes sense given how widely studied it is, but the broader class of incretin-based drugs could eventually benefit from this line of research.

Where This Research Stands Right Now

It is important to be direct about what this discovery is and what it is not. This is early-stage laboratory research. The studies were conducted in controlled lab settings, not in humans. There is no enzyme-blocking drug approved or in late-stage clinical trials yet.

The path from a promising lab finding to an approved medication typically takes years, involving animal studies, Phase 1 safety trials in healthy volunteers, Phase 2 efficacy trials, and Phase 3 large-scale trials before any regulatory review by the FDA.

Here is a rough timeline of what drug development stages typically look like:

This means a drug that incorporates enzyme-blocking technology or an enzyme-resistant semaglutide formulation is realistically at least 5 to 10 years away from patient use. Current medications remain the best available options today.

What This Could Mean for Cost and Access

One of the most persistent barriers to GLP-1 therapy is cost. Ozempic and Wegovy list prices can exceed $900 to $1,300 per month without insurance. Even with manufacturer savings programs, many patients face significant out-of-pocket expenses.

A longer-acting formulation could potentially reduce dosing frequency from weekly to monthly. If a single monthly dose replaces four weekly doses, and pricing reflects that reduction even partially, patients could see real cost savings. Additionally, fewer doses per year means fewer pharmacy pickups, fewer injection supplies, and less disruption to daily routines.

That said, pharmaceutical pricing does not always follow a simple dose-per-dollar logic. Monthly formulations of other drugs have not always been cheaper than their weekly equivalents. Patients and advocacy groups would need to push for pricing structures that reflect the actual reduction in drug volume used.

If you are currently navigating the cost of GLP-1 therapy, the GLP-1 Coupons page on GLP-1.com has current savings options for FDA-approved medications.

Questions to Ask Your Doctor

Even though this research has not changed current treatment, it is worth understanding how it connects to your care. Here are practical questions to raise at your next appointment:

• I have read about a newly discovered enzyme that breaks down GLP-1 hormones through a pathway separate from DPP-4. Does that finding change anything about how you think about my current semaglutide or tirzepatide dosing or formulation?
• I sometimes notice that my appetite control feels weaker toward the end of the week before my next injection. Could that be related to drug level fluctuation during the week, and is there anything we can do about it within my current treatment plan?
• If longer-acting GLP-1 formulations eventually reach clinical trials, would I be a candidate for participating in those trials, and how would I find out about opportunities as they become available?
• Given that this enzyme may also affect tirzepatide's GLP-1 component, does that influence whether you would recommend semaglutide or tirzepatide for someone in my situation if a longer-acting option were available sooner for one versus the other?
• If monthly dosing eventually becomes possible with next-generation GLP-1 drugs, does that change your thinking about long-term adherence for someone like me, and would you expect better outcomes with less frequent dosing?
• Are there any steps I can take now, such as timing my injection on a specific day of the week or adjusting my diet toward the end of the dosing cycle, to minimize the blood level fluctuation I notice before my next dose?

Your prescribing provider is your best resource for understanding how evolving science applies to your specific health profile. No medication decision should be made based on early-stage research alone.